The anesthesia and respiratory devices market is projected to grow from USD 53.5 billion in 2025 to USD 71.3 billion in 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 5.9%.
Anesthesia devices are critical for delivering anesthetic agents to patients undergoing medical procedures. A controlled and steady flow of anesthesia is essential throughout a procedure to mitigate pain and sensation, facilitating surgical, medical, and psychiatric interventions.
Respiratory devices, conversely, ensure adequate oxygen flow to the body during these procedures. They are also indispensable for patients with severe chronic lung conditions (such as asthma, chronic obstructive pulmonary diseases (COPD), or lung cancer) whose natural respiratory systems cannot meet the body's oxygen requirements. The concurrent use of anesthesia and respiratory devices during surgery allows for reduced sensation or induced sleep without compromising respiratory function.
The increasing global incidence of chronic diseases is a fundamental driver of market growth. A rise in chronic disease diagnoses, particularly for severe conditions, directly correlates with an elevated need for surgical interventions and medical equipment, thus stimulating demand for anesthesia and respiratory devices.
Expanding healthcare infrastructure and increased expenditure contribute to the construction of new medical facilities, consequently elevating demand for this equipment. Furthermore, the growing aging population and associated age-linked health complexities drive demand for respiratory devices to manage pulmonary and other chronic conditions. Technological innovation within the industry also supports market expansion.
Growing instances of chronic diseases have created robust demand for anesthesia and respiratory devices.
The escalating prevalence of chronic diseases requiring medical intervention represents a significant market driver. Data from the Centers for Disease Control and Prevention (CDC) indicates that in America, six out of ten adults suffer from a chronic disease, with four of those experiencing more than one. In Australia, one in five adults contends with over two chronic diseases, and one in every two hospitalizations is linked to the severity of chronic conditions (Source: Australian Institute of Health and Welfare). Chronic diseases were responsible for nine out of ten deaths in Australia in 2018.
Cardiovascular disease (CVD) remains the most common chronic disease globally. The World Health Organization (WHO) reports that CVD is the leading cause of death worldwide, accounting for over 30% of global fatalities annually. Rising air pollution has contributed to an increase in lung diseases and lung cancer cases. Additionally, demanding workloads and complex lifestyles have amplified the incidence of CVDs and gastric conditions that necessitate medical attention. These factors collectively underscore the critical need for advanced medical attention, life-saving procedures, and preventative measures, thereby expanding the market for anesthesia and respiratory devices.
Growing medical tourism will provide humongous growth prospects for the Asia Pacific region which will drive the regional anesthesia and respiratory device market.
The expansion of medical tourism presents substantial growth opportunities for the Asia Pacific region, directly influencing the regional anesthesia and respiratory device market. Analysis of regional markets indicates robust growth for the Asia Pacific Anesthesia and Respiratory Devices Market throughout the forecast period. This growth is underpinned by infrastructure development, the adoption of modern technology, and the availability of affordable, high-quality healthcare services.
The region has observed a consistent increase in medical tourists seeking advanced treatments, particularly in Thailand, Malaysia, India, Singapore, and South Korea. A key attraction is the cost-effectiveness of medical services. Healthcare.org reports that opting for medical surgeries and procedures in the Asia Pacific region can reduce costs for a U.S. household by up to 90% to 95% compared to domestic treatment.
Favorable government policies aimed at attracting both medical and general tourists are expected to broaden the market scope for the Asia Pacific region during the forecast period. For example, in January 2019, the Indian government revised its e-visa rules, extending validity from 60 days to one year. In October 2020, the Thai government introduced a specialized visa for medical tourists, permitting stays exceeding 200 days. These initiatives, coupled with increased government healthcare expenditure to improve infrastructure for domestic and international patients, are anticipated to support growth in both medical tourism and the anesthesia and respiratory devices markets.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 53.5 billion |
| Total Market Size in 2030 | USD 71.3 billion |
| Forecast Unit | Billion |
| Growth Rate | 5.9% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Products, End-User, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|